Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNYSE:MNK
CUSIPN/A
Phone44-0-17-8463-6700
Debt
Debt-to-Equity Ratio1.00
Current Ratio2.10
Quick Ratio1.90
Price-To-Earnings
Trailing P/E Ratio3.07
Forward P/E Ratio3.48
P/E Growth0.36
Sales & Book Value
Annual Sales$3.22 billion
Price / Sales0.56
Cash Flow$16.0444 per share
Price / Cash1.35
Book Value$68.65 per share
Price / Book0.32
Profitability
EPS (Most Recent Fiscal Year)$7.49
Net Income$2.13 billion
Net Margins57.56%
Return on Equity11.59%
Return on Assets4.48%
Miscellaneous
Employees3,900
Outstanding Shares83,080,000
Market Cap$1,819.56
Mallinckrodt (NYSE:MNK) Frequently Asked Questions
What is Mallinckrodt's stock symbol?
Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."
How will Mallinckrodt's stock buyback program work?
Mallinckrodt announced that its board has approved a stock buyback program on Sunday, April 9th 2017, which authorizes the company to buyback $1,000,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 18.5% of its stock through open market purchases. Stock buyback programs are typically a sign that the company's management believes its stock is undervalued.
How were Mallinckrodt's earnings last quarter?
Mallinckrodt PLC (NYSE:MNK) issued its earnings results on Tuesday, May, 8th. The company reported $1.31 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $1.08 by $0.23. The business earned $572.60 million during the quarter, compared to the consensus estimate of $568.78 million. Mallinckrodt had a net margin of 57.56% and a return on equity of 11.59%. The firm's revenue for the quarter was up 2.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.04 EPS. View Mallinckrodt's Earnings History.
When is Mallinckrodt's next earnings date?
What price target have analysts set for MNK?
19 equities research analysts have issued 12-month target prices for Mallinckrodt's shares. Their forecasts range from $12.00 to $67.00. On average, they expect Mallinckrodt's stock price to reach $30.8947 in the next year. This suggests a possible upside of 42.6% from the stock's current price. View Analyst Ratings for Mallinckrodt.
What is the consensus analysts' recommendation for Mallinckrodt?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mallinckrodt in the last year. There are currently 1 sell rating, 13 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Mallinckrodt stock?
Here are some recent quotes from research analysts about Mallinckrodt stock:
- 1. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) YTD (today), total debt has decreased by roughly ~$215MM. the end of 1Q18 was 4.6x, an expected increase from last quarter, following the close of the SCMP deal., 2) MNK presented its free cash flow guidance for the first time. This is expected to be ~$0.5B in 2018. Operating cash flow in 1Q18 of ~$18MM was impacted primarily by assumed liabilities paid following the close of the SCMP transaction. MNK expects free cash flow to return to more normal levels the remainder of the year., 3) While debt reduction is MNK’s top priority with respect to capital allocation for 2018, MNK did repurchase 2.9MM shares in 1Q18." (5/8/2018)
- 2. Mizuho analysts commented, "We plan to remove all risk-adjusted estimates for this compound from our model after the earnings call, which will be somewhat offset by the greater than $0.15-$0.20 in dilution to adjusted earnings expected in 2018″." (5/3/2018)
- 3. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax. As a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018)
Who are some of Mallinckrodt's key competitors?
Some companies that are related to Mallinckrodt include Alkermes (ALKS), Catalent (CTLT), Ionis Pharmaceuticals (IONS), United Therapeutics (UTHR), FibroGen (FGEN), Loxo Oncology (LOXO), GALAPAGOS NV/S (GLPG), Agios Pharmaceuticals (AGIO), Ligand Pharmaceuticals (LGND), Dr.Reddy's Laboratories (RDY), Taro Pharmaceutical Industries (TARO), HUTCHISON CHINA/S (HCM), Ultragenyx Pharmaceutical (RARE), GW Pharmaceuticals (GWPH) and Madrigal Pharmaceuticals (MDGL).
Who are Mallinckrodt's key executives?
Mallinckrodt's management team includes the folowing people:
- Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)
- Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)
- Dr. Frank Scholz, Exec. VP and Chief Operations & Digital Innovation Officer (Age 49)
- Mr. Hugh M. O'Neill, Exec. VP & Chief Commercial Officer (Age 55)
- Ms. Kathleen A. Schaefer, Sr. VP, Principal Accounting Officer & Corp. Controller
Has Mallinckrodt been receiving favorable news coverage?
Media headlines about MNK stock have trended somewhat positive this week, according to Accern. Accern identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Mallinckrodt earned a media sentiment score of 0.08 on Accern's scale. They also gave press coverage about the company an impact score of 45.93 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Mallinckrodt's major shareholders?
Mallinckrodt's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Jabodon PT Co. (0.32%), James Investment Research Inc. (0.18%), Retirement Systems of Alabama (0.13%), Bank of Montreal Can (0.08%), Municipal Employees Retirement System of Michigan (0.02%) and Hartford Investment Management Co. (0.02%). Company insiders that own Mallinckrodt stock include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, James E Flynn, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Institutional Ownership Trends for Mallinckrodt.
Which institutional investors are selling Mallinckrodt stock?
MNK stock was sold by a variety of institutional investors in the last quarter, including Municipal Employees Retirement System of Michigan, Amalgamated Bank, Retirement Systems of Alabama and Nisa Investment Advisors LLC. View Insider Buying and Selling for Mallinckrodt.
Which institutional investors are buying Mallinckrodt stock?
MNK stock was bought by a variety of institutional investors in the last quarter, including James Investment Research Inc., Bank of Montreal Can, Jabodon PT Co. and Hartford Investment Management Co.. Company insiders that have bought Mallinckrodt stock in the last two years include Coleman N Lannum III, David R Carlucci, Dr Kneeland Youngblood, Hugh M O'neill, Joann A Reed, Mark Trudeau, Matthew K Harbaugh, Meredith B Fischer, Michael-Bryant Hicks and Steven J Romano. View Insider Buying and Selling for Mallinckrodt.
How do I buy shares of Mallinckrodt?
Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Mallinckrodt's stock price today?
One share of MNK stock can currently be purchased for approximately $21.66.
How big of a company is Mallinckrodt?
Mallinckrodt has a market capitalization of $1.82 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.
How can I contact Mallinckrodt?
Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY STAINES-UPON-THAMES, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]
MarketBeat Community Rating for Mallinckrodt (NYSE MNK)
MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.
